AMGN AM

AMGN Amgen Inc.

Healthcare · Drug Manufacturers - General

6 · Fair Watch 14y streak

358.33

+1.56%

About the company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

2.81% 70.15% 10.08 24.94 14.37 333.61
52w 269.77 391.29

Dividend profile

Frequency Quarterly Growth (TTM) +5.8% CAGR 3y +7.1% +8.3% 14 years

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Debt & leverage

623.75% 1.26 0.85 Total debt 57.3B USD Total cash 12.0B USD 16.9B USD

Latest reported balance-sheet figures.

Held by 1 investor

Sign up for an AI summary of this stock's dividend — and to track it in your portfolio.

Information, not financial advice.

The information on Quantic is provided for informational and educational purposes only. It is general in nature, does not take into account your personal financial situation, and does not constitute investment, financial, tax, or legal advice — nor a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal; past performance is not a reliable indicator of future results. Market data comes from third-party providers and may be delayed or inaccurate. Before making any investment decision, consider your objectives, time horizon, risk tolerance, and diversification, and consult a qualified financial professional. Quantic is not a registered investment adviser or broker-dealer.

Quantic finance

Built with Elixir, Phoenix LiveView, and Tailwind CSS

© 2026 Francesc Leveque · Learn · Frequently Asked Questions